Results 101 to 110 of about 1,029,181 (225)

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings

International Journal of Methods in Psychiatric Research, Volume 35, Issue 2, June 2026.
ABSTRACT Objectives For English, the validated part of Psychedelic Experience Scale (PES48) is a four‐factor structure called the Mystical Experience Questionnaire (MEQ30). The other validated part of the PES48 consists of four more factors: two more mystical factors (paradoxicality and connectedness, which together with the MEQ30 form the MEQ40), and ...
Kurt Stocker, Matthias Hartmann, Frederick S. Barrett, William A. Richards, Nathan D. Sepeda, Laura Ley, Anna M. Becker, Friederike Holze, Matthias E. Liechti   +8 more
wiley   +1 more source

Online drug user-led harm reduction in Hungary: a review of "Daath". [PDF]

, 2013
Harm reduction has been increasingly finding its way into public drug policies and healthcare practices worldwide, with successful intervention measures justifiably focussing on the highest-risk groups, such as injecting drug users.
Móró Levente,, Rácz, József
core   +2 more sources

Psilocybin Production With Genetically Modified Aspergillus nidulans Under Pressurized Conditions

Biotechnology and Bioengineering, Volume 123, Issue 4, Page 886-898, April 2026.
Shake flask cultures of psilocybin‐producing A. nidulans were investigated with respect to nitrogen source, rheology, power input, and oxygen availability, and subsequently scaled to a stirred tank reactor scale based on specific power input to develop and optimize a pressurized bioprocess.
Sophie Weiser, Sidney Jung, Bettina Bardl, Johann E. Kufs, Slavica Janevska, Vito Valiante, Dirk Hoffmeister, Lars Regestein   +7 more
wiley   +1 more source

Investigating Emotional Reactivity in Experienced Users of Psychedelics: A Cross‐Sectional fMRI Study

Human Brain Mapping, Volume 47, Issue 5, 1 April 2026.
This cross‐sectional fMRI study compared experienced psychedelic users and matched nonusers on behavioral and neural responses to emotional facial expressions. Findings reveal neurofunctional differences between groups in emotional reactivity, highlighting both similarities and important distinctions in the long‐term effects of naturalistic versus ...
Paweł Orłowski, Aleksandra Domagalik, Michał Bola   +2 more
wiley   +1 more source

Structural characterization and comparative analysis of polymorphic forms of psilocin (4-hydroxy-N,N-dimethyltryptamine)

Acta Crystallographica Section E: Crystallographic Communications
The title compound, C12H16N2O, is a hydroxy-substituted monoamine alkaloid, and the primary metabolite of the naturally occurring psychedelic compound psilocybin.
Matthias Zeller, Stephan Parent, Nate Schultheiss   +2 more
doaj   +1 more source

Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
ABSTRACT Major Depressive Disorder (MDD) and chronic pain are independently debilitating conditions that frequently co‐occur. This comorbidity poses a significant clinical challenge, resulting in greater symptom severity, higher disability, and worse prognosis than either condition alone.
Jordana Kazdan, Karim S. Ladha, M. Ishrat Husain   +2 more
wiley   +1 more source

The void and the brain

Cell Reports
Blackburne et al. track the electroencephalogram activity of volunteers inhaling a high dose of the powerful psychedelic 5-methoxy-N,N-dimethyltryptamine, revealing profoundly slowed-down brain activity but no significant reduction of alpha band power ...
Christof Koch
doaj   +1 more source

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study [PDF]

, 2018
Rationale: Serotonin (5-Hydroxytryptamine, 5-HT) receptors play an important role in perception, affect regulation and attention. Pharmacological challenge with the 5-HT2A agonist psilocybin (PY) is useful in studying the neurobiological basis of ...
Benz, Marco, Grimberg, Ulrike, Hasler, Felix, Huber, Theo, Vollenweider, Franz   +4 more
core